{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:45:51Z","timestamp":1792784751936,"version":"4.5.0"},"reference-count":98,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100014455","name":"University of Tennessee, Knoxville","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014455","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Nuclear Engineering, University of Tennessee, Knoxville","id":[{"id":"https:\/\/ror.org\/020f3ap87","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of 134Ce as both a positron-emitting surrogate for 225Ac and a therapeutic Auger and conversion-electron (ACE) emitter has accelerated rapidly in recent years, positioning it as one of the most versatile emerging radionuclides for targeted radiopharmaceuticals. Existing PET radionuclides used as imaging surrogates for 225Ac\ue5f8including 64Cu, 68Ga, and 89Zr\ue5f8suffer from kinetic, chemical, and dosimetric mismatches that limit their ability to accurately predict the biodistribution of the long-lived alpha emitter and the in vivo redistribution of its radioactive daughters. Lanthanum-based radionuclides (132La, 133La) offer improved chemical compatibility but face production challenges, imaging limitations, and sparse in vivo validation. In contrast, the 134Ce\/134La pair offers the dual advantage of being an f-block element with chemistry closely mirroring that of 225Ac and whose high positron branching ratio (63.6%) and long half-life (t1\/2 = 3.16 days) enable extended-time PET imaging, specifically with longer half-life macromolecules in vivo. Recent studies have demonstrated gigabecquerel (GBq) scale production of high-purity 134Ce, robust chelation strategies, and strong matched-pair performance with 225Ac across small molecules, antibodies, and pretargeting systems. Moreover, the first therapeutic application of 134Ce\/134La therapies with ACEs and positrons has shown potent, PSMA-specific tumor repression with minimal off-target toxicity, highlighting its promise as a dual-function theranostic radionuclide. Collectively, the growing body of work on 134Ce establishes it as a compelling next-generation imaging surrogate for [225Ac]Ac-based radiopharmaceuticals and a potential therapeutic candidate through the utilization of its ACEs and positrons. In this review, we summarize the current progress in the development of [134Ce]Ce-based radiopharmaceuticals, highlighting studies reported to date for both imaging and therapeutic applications, and discuss the opportunities and challenges that must be addressed to advance this matched radionuclide pair toward clinical translation.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00722","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:40:52Z","timestamp":1788435652000},"page":"4789-4804","source":"Crossref","is-referenced-by-count":0,"title":["134Ce\/134La Radiotheranostics from PET Surrogation of 225Ac to Auger and Conversion-Electron Therapy"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8055-6898","authenticated-orcid":true,"given":"Albin","family":"Brejeon","sequence":"first","affiliation":[{"name":"University of Tennessee-Knoxville , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngho","family":"Seo","sequence":"additional","affiliation":[{"name":"University of California , , , ,","place":["San Francisco, California, United States, 94107"]},{"name":"UCSF Helen Diller Family Comprehensive Cancer Center , , ,","place":["San Francisco, California, United States, 94143-0981"]},{"name":"University of California , , , ,","place":["Berkeley, California, United States, 94720"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2849-0841","authenticated-orcid":true,"given":"Henry F.","family":"VanBrocklin","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center , , ,","place":["San Francisco, California, United States, 94143-0981"]},{"name":"University of California , , , ,","place":["Berkeley, California, United States, 94720"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8694-1199","authenticated-orcid":true,"given":"Robert R.","family":"Flavell","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center , , ,","place":["San Francisco, California, United States, 94143-0981"]},{"name":"University of California , , , ,","place":["Berkeley, California, United States, 94720"]},{"name":"University of California , , , ,","place":["San Francisco, California, United States, 94158-2517"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kondapa Naidu","family":"Bobba","sequence":"additional","affiliation":[{"name":"University of Tennessee-Knoxville , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"issue":"8","key":"2026100509320201400_cit1","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"2026100509320201400_cit2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.47102\/annals-acadmedsg.v33n2p133","article-title":"Physical principles and technology of clinical PET imaging","volume":"33","author":"Townsend","year":"2004","journal-title":"Ann. Acad. Med. Singap."},{"key":"2026100509320201400_cit3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06077.x","article-title":"Fundamentals of PET and PET\/CT imaging","volume":"1228","author":"Basu","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"22","key":"2026100509320201400_cit4","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.3390\/s19225019","article-title":"Sensors for Positron Emission Tomography Applications","volume":"19","author":"Jiang","year":"2019","journal-title":"Sensors"},{"issue":"3","key":"2026100509320201400_cit5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12194-024-00821-x","article-title":"PET detectors with depth-of-interaction and time-of-flight capabilities","volume":"17","author":"Yoshida","year":"2024","journal-title":"Radiol. Phys. Technol."},{"issue":"9","key":"2026100509320201400_cit6","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms23095023","article-title":"Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade","volume":"23","author":"Cris\u0327an","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026100509320201400_cit7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/MNM.0b013e32834c13b5","article-title":"Combining dynamic and ECG-gated 82Rb-PET for practical implementation in the clinic","volume":"33","author":"Sayre","year":"2012","journal-title":"Nucl. Med. Commun."},{"issue":"4","key":"2026100509320201400_cit8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2967\/jnumed.106.032680","article-title":"Recent Advances in SPECT Imaging","volume":"48","author":"Madsen","year":"2007","journal-title":"J. Nucl. Med."},{"key":"2026100509320201400_cit9","doi-asserted-by":"publisher","first-page":"796025","DOI":"10.1155\/2011\/796025","article-title":"Molecular SPECT Imaging: An Overview","volume":"2011","author":"Khalil","year":"2011","journal-title":"Int. J. Mol. Imaging"},{"issue":"2","key":"2026100509320201400_cit10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jsps.2022.12.013","article-title":"SPECT\/CT and PET\/CT, related radiopharmaceuticals, and areas of application and comparison","volume":"31","author":"Alqahtani","year":"2023","journal-title":"Saudi Pharm. J."},{"issue":"5","key":"2026100509320201400_cit11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/01.Hp.0000334064.46217.20","article-title":"Combined imaging modalities: PET\/CT and SPECT\/CT","volume":"95","author":"Maurer","year":"2008","journal-title":"Health Phys."},{"issue":"4","key":"2026100509320201400_cit12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s13246-018-0684-1","article-title":"Eric J. Hall and Amato J. Giaccia: Radiobiology for the radiologist","volume":"41","author":"Douglass","year":"2018","journal-title":"Australas. Phys. Eng. Sci. Med."},{"issue":"2","key":"2026100509320201400_cit13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026100509320201400_cit14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mednuc.2017.12.002","article-title":"Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects","volume":"42","author":"Lacoeuille","year":"2018","journal-title":"Med. Nucl."},{"key":"2026100509320201400_cit15","doi-asserted-by":"publisher","first-page":"1020188","DOI":"10.3389\/fmed.2022.1020188","article-title":"Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?","volume":"9","author":"Pallares","year":"2022","journal-title":"Front. Med."},{"issue":"5","key":"2026100509320201400_cit16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00259-005-1803-2","article-title":"Cancer radioimmunotherapy with alpha-emitting nuclides","volume":"32","author":"Couturier","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026100509320201400_cit17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13550-025-01214-w","article-title":"In silico analysis of radiation-induced double-strand breaks by internal ex vivo irradiation of lymphocytes for 45 alpha- and beta\/gamma-emitting radionuclides","volume":"15","author":"Salas-Ramirez","year":"2025","journal-title":"EJNMMI Res."},{"issue":"5","key":"2026100509320201400_cit18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1667\/rade-20-00235.1","article-title":"Lethal DNA Lesions Caused by Direct and Indirect Actions of X rays are Repaired via Different DSB Repair Pathways under Aerobic and Anoxic Conditions","volume":"195","author":"Hirayama","year":"2021","journal-title":"Radiat. Res."},{"issue":"12","key":"2026100509320201400_cit19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.addr.2008.04.007","article-title":"Alpha-particles for targeted therapy","volume":"60","author":"Sgouros","year":"2008","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026100509320201400_cit20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting \u03b1-particles or Auger electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv. Drug Delivery Rev."},{"issue":"1","key":"2026100509320201400_cit21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy - a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"14","key":"2026100509320201400_cit22","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.3390\/ijms241411626","article-title":"Targeted Alpha-Particle Therapy: A Review of Current Trials","volume":"24","author":"Jang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"2026100509320201400_cit23","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3390\/ph16111622","article-title":"Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications","volume":"16","author":"Nelson","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"10","key":"2026100509320201400_cit24","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1158\/1078-0432.Ccr-22-3291","article-title":"Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy","volume":"29","author":"Bidkar","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"2026100509320201400_cit25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1021\/acs.molpharmaceut.4c01071","article-title":"Preclinical Comparison of [(111)In]In- and [(225)Ac]Ac-DOTA-Trastuzumab IgG, F(ab\u2019)(2) and Fab for Theranostic SPECT\/CT Imaging and \u03b1-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer","volume":"22","author":"Kondo","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"2026100509320201400_cit26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1053\/j.semnuclmed.2025.06.008","article-title":"Advances With (225)Ac-DOTATATE Targeted Alpha Therapy in Somatostatin Receptor Positive Neuroendocrine Tumors","volume":"55","author":"Chandekar","year":"2025","journal-title":"Semin. Nucl. Med."},{"issue":"8","key":"2026100509320201400_cit27","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-based dosimetry for [(225)Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026100509320201400_cit28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.nucmedbio.2022.04.005","article-title":"Promising theranostic radionuclides for PET, alpha, and Auger-Meitner therapy","volume":"110\u2212111","author":"Nelson","year":"2022","journal-title":"Nucl. Med. Biol."},{"issue":"3","key":"2026100509320201400_cit29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41557-020-00598-7","article-title":"Developing the (134)Ce and (134)La pair as companion positron emission tomography diagnostic isotopes for (225)Ac and (227)Th radiotherapeutics","volume":"13","author":"Bailey","year":"2021","journal-title":"Nat. Chem."},{"issue":"7","key":"2026100509320201400_cit30","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2967\/jnumed.122.265355","article-title":"Evaluation of (134)Ce\/(134)La as a PET Imaging Theranostic Pair for (225)Ac \u03b1-Radiotherapeutics","volume":"64","author":"Bobba","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026100509320201400_cit31","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1038\/s41598-022-07147-x","article-title":"PET in vivo generators 134Ce and 140Nd on an internalizing monoclonal antibody probe","volume":"12","author":"Severin","year":"2022","journal-title":"Sci. Rep."},{"key":"2026100509320201400_cit32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.nucmedbio.2022.04.007","article-title":"Evaluation of 134Ce as a PET imaging surrogate for antibody drug conjugates incorporating 225Ac","volume":"110\u2212111","author":"Bailey","year":"2022","journal-title":"Nucl. Med. Biol."},{"issue":"4","key":"2026100509320201400_cit33","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.7150\/thno.92742","article-title":"Development of CD46 targeted alpha theranostics in prostate cancer using (134)Ce\/(225)Ac-Macropa-PEG(4)-YS5","volume":"14","author":"Bobba","year":"2024","journal-title":"Theranostics"},{"issue":"13","key":"2026100509320201400_cit34","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1007\/s00259-024-06811-w","article-title":"Examination of the PET in vivo generator (134)Ce as a theranostic match for (225)Ac","volume":"51","author":"Bauer","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"2026100509320201400_cit35","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2967\/jnumed.125.269751","article-title":"Evaluation of (134)Ce\/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer","volume":"66","author":"Bobba","year":"2025","journal-title":"J. Nucl. Med."},{"key":"2026100509320201400_cit36","volume-title":"NuDat (Nuclear Structure and Decay Data)","author":"National Nuclear Data Center"},{"issue":"4","key":"2026100509320201400_cit37","doi-asserted-by":"publisher","first-page":"100065","DOI":"10.1016\/j.craph.2026.100065","article-title":"Convergence methodologies for PSMA-targeted radiotheranostics: A transformative blueprint for precision prostate cancer management","volume":"19","author":"Khan","year":"2026","journal-title":"Curr. Radiopharm."},{"issue":"1","key":"2026100509320201400_cit38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/08998280.2019.1678338","article-title":"Use of (68)Ga DOTATATE, a new molecular imaging agent, for neuroendocrine tumors","volume":"33","author":"LeBlanc","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"12","key":"2026100509320201400_cit39","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-Targeted \u03b1-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026100509320201400_cit40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026100509320201400_cit41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/138161207779313768","article-title":"Copper chelation chemistry and its role in copper radiopharmaceuticals","volume":"13","author":"Wadas","year":"2007","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"2026100509320201400_cit42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nucmedbio.2012.08.004","article-title":"PET imaging with 89Zr: from radiochemistry to the clinic","volume":"40","author":"Deri","year":"2013","journal-title":"Nucl. Med. Biol."},{"issue":"8","key":"2026100509320201400_cit43","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/cbr.2018.2494","article-title":"Actinium-225 for Targeted \u03b1 Therapy: Coordination Chemistry and Current Chelation Approaches","volume":"33","author":"Thiele","year":"2018","journal-title":"Cancer Biother. Radiopharm."},{"issue":"9","key":"2026100509320201400_cit44","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1097\/mnm.0000000000001422","article-title":"Production of copper-64 using a hospital cyclotron: targetry, purification and quality analysis","volume":"42","author":"Jauregui-Osoro","year":"2021","journal-title":"Nucl. Med. Commun."},{"issue":"4","key":"2026100509320201400_cit45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: (64)Cu- and (225)Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models","volume":"61","author":"Watabe","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"4","key":"2026100509320201400_cit46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.nucmedbio.2014.01.006","article-title":"Production of 89Zr via the 89Y(p,n) 89Zr reaction in aqueous solution: effect of solution composition on in-target chemistry","volume":"41","author":"Pandey","year":"2014","journal-title":"Nucl. Med. Biol."},{"issue":"5","key":"2026100509320201400_cit47","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.Ccr-23-2130","article-title":"CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma","volume":"30","author":"Wadhwa","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"2026100509320201400_cit48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.nucmedbio.2022.02.003","article-title":"Radiation dosimetry and efficacy of an (89)Zr\/(225)Ac-labeled humanized anti-MUC5AC antibody","volume":"108\u2212109","author":"Nakata","year":"2022","journal-title":"Nucl. Med. Biol."},{"issue":"23","key":"2026100509320201400_cit49","doi-asserted-by":"publisher","first-page":"25607","DOI":"10.1021\/acs.jmedchem.5c02837","article-title":"Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas","volume":"68","author":"Zheng","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026100509320201400_cit50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s41181-024-00258-y","article-title":"Good practices for (89)Zr radiopharmaceutical production and quality control","volume":"9","author":"Wuensche","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"7","key":"2026100509320201400_cit51","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2967\/jnumed.118.214726","article-title":"Immuno-PET Imaging to Assess Target Engagement: Experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors","volume":"60","author":"Menke-van der Houven van Oordt","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"11","key":"2026100509320201400_cit52","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1021\/acs.bioconjchem.4c00274","article-title":"Click Chemistry Enables [(89)Zr]Zr-DOTA Radioimmunoconjugation for Theranostic (89)Zr-immunoPET","volume":"35","author":"Imura","year":"2024","journal-title":"Bioconjugate Chem."},{"key":"2026100509320201400_cit53","doi-asserted-by":"publisher","first-page":"108943","DOI":"10.1016\/j.nucmedbio.2024.108943","article-title":"[(89)Zr]ZrCl(4) for direct radiolabeling of DOTA-based precursors","volume":"136\u2212137","author":"Lyashchenko","year":"2024","journal-title":"Nucl. Med. Biol."},{"issue":"6","key":"2026100509320201400_cit54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1524\/ract.2007.95.6.319","article-title":"A 140Nd\/140Pr radionuclide generator based on physico-chemical transitions in 140Pr complexes after electron capture decay of 140Nd-DOTA","volume":"95","author":"Zhernosekov","year":"2007","journal-title":"Radiochim. Acta"},{"issue":"1","key":"2026100509320201400_cit55","doi-asserted-by":"publisher","first-page":"34991","DOI":"10.1038\/s41598-025-18929-4","article-title":"Production and radiochemistry of the in vivo PET generator (140)Nd\/(140)Pr as an imaging surrogate for F-block therapeutic radionuclides","volume":"15","author":"Godara","year":"2025","journal-title":"Sci. Rep."},{"key":"2026100509320201400_cit56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fmed.2017.00098","article-title":"Neodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing Vector","volume":"4","author":"Severin","year":"2017","journal-title":"Front. Med."},{"issue":"9","key":"2026100509320201400_cit57","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1021\/acs.inorgchem.5c05846","article-title":"Stabilities of Ac(3+) Complexes Relevant as Radiopharmaceuticals","volume":"65","author":"Freire-Garci\u0301a","year":"2026","journal-title":"Inorg. Chem."},{"issue":"1","key":"2026100509320201400_cit58","doi-asserted-by":"publisher","first-page":"10658","DOI":"10.1038\/s41598-019-47137-0","article-title":"Production and in vivo PET\/CT imaging of the theranostic pair (132\/135)La","volume":"9","author":"Aluicio-Sarduy","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"2026100509320201400_cit59","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.2967\/jnumed.120.255794","article-title":"Cyclotron-Produced (132)La as a PET Imaging Surrogate for Therapeutic (225)Ac","volume":"62","author":"Aluicio-Sarduy","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"4","key":"2026100509320201400_cit60","doi-asserted-by":"publisher","first-page":"584","DOI":"10.2967\/jnumed.121.262459","article-title":"First In Vivo and Phantom Imaging of Cyclotron-Produced (133)La as a Theranostic Radionuclide for (225)Ac and (135)La","volume":"63","author":"Nelson","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026100509320201400_cit61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41181-025-00354-7","article-title":"It\u2019s a match: use of the radionuclide theranostic pair (133)La\/(225)Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies","volume":"10","author":"Trommer","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"18","key":"2026100509320201400_cit62","doi-asserted-by":"publisher","first-page":"185009","DOI":"10.1088\/1361-6560\/ac8b5f","article-title":"SPECT imaging of(226)Ac as a theranostic isotope for(225)Ac radiopharmaceutical development","volume":"67","author":"Koniar","year":"2022","journal-title":"Phys. Med. Biol."},{"issue":"11","key":"2026100509320201400_cit63","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.2967\/jnumed.124.267999","article-title":"Preclinical Evaluation of (226)Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy","volume":"65","author":"Koniar","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026100509320201400_cit64","doi-asserted-by":"publisher","first-page":"109828","DOI":"10.1016\/j.apradiso.2021.109828","article-title":"Simple and efficient method for producing high radionuclidic purity (111)In using enriched (112)Cd target","volume":"176","author":"Gao","year":"2021","journal-title":"Appl. Radiat. Isot."},{"issue":"1","key":"2026100509320201400_cit65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41181-023-00208-0","article-title":"[(225)Ac]Ac- and [(111)In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts","volume":"8","author":"Kondo","year":"2023","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"12","key":"2026100509320201400_cit66","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1021\/acs.molpharmaceut.9b00542","article-title":"111In- and (225)Ac-Labeled Cixutumumab for Imaging and \u03b1-Particle Radiotherapy of IGF-1R Positive Triple-Negative Breast Cancer","volume":"16","author":"Solomon","year":"2019","journal-title":"Mol. Pharmaceutics"},{"issue":"15","key":"2026100509320201400_cit67","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.7150\/thno.38236","article-title":"Preclinical evaluation of an (111)In\/(225)Ac theranostic targeting transformed MUC1 for triple negative breast cancer","volume":"10","author":"Kelly","year":"2020","journal-title":"Theranostics"},{"key":"2026100509320201400_cit68","article-title":"A new radionuclide generator for positron emission tomography: Development of cerium-134\/lanthanum-134 system","volume":"35","author":"Zweit","year":"1994","journal-title":"J. Nucl. Med."},{"issue":"4","key":"2026100509320201400_cit69","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1088\/0031-9155\/47\/4\/305","article-title":"Production, PET performance and dosimetric considerations of 134Ce\/134La, an Auger electron and positron-emitting generator for radionuclide therapy","volume":"47","author":"Lubberink","year":"2002","journal-title":"Phys. Med. Biol."},{"issue":"2","key":"2026100509320201400_cit70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?","volume":"8","author":"de Kruijff","year":"2015","journal-title":"Pharmaceuticals"},{"issue":"16","key":"2026100509320201400_cit71","first-page":"5084","article-title":"Targeted Actinium-225 in Vivo Generators for Therapy of Ovarian Cancer","volume":"63","author":"Borchardt","year":"2003","journal-title":"Cancer Res."},{"issue":"1","key":"2026100509320201400_cit72","doi-asserted-by":"publisher","first-page":"18837","DOI":"10.1038\/s41598-023-43429-8","article-title":"Preclinical evaluation of [(58m)Co]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer","volume":"13","author":"Baun","year":"2023","journal-title":"Sci. Rep."},{"issue":"5","key":"2026100509320201400_cit73","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00259-006-0254-8","article-title":"Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium\/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo","volume":"34","author":"Schipper","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026100509320201400_cit74","doi-asserted-by":"publisher","first-page":"582","DOI":"10.2967\/jnumed.108.056366","article-title":"Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In","volume":"50","author":"Liu","year":"2009","journal-title":"J. Nucl. Med."},{"issue":"4","key":"2026100509320201400_cit75","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.3390\/ijms24043083","article-title":"Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer","volume":"24","author":"Sreekumar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"2026100509320201400_cit76","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.2967\/jnumed.123.265429","article-title":"[(123)I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer","volume":"64","author":"Chan","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"7","key":"2026100509320201400_cit77","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.7150\/thno.38882","article-title":"Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer","volume":"10","author":"Shen","year":"2020","journal-title":"Theranostics"},{"key":"2026100509320201400_cit78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-58223-5","article-title":"Evaluation of radiation damage effects of low-energy Auger and conversion electrons emitted by 134Ce decay using a Monte Carlo method","author":"Lee","year":"2026","journal-title":"Sci. Rep."},{"issue":"6","key":"2026100509320201400_cit79","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1088\/1361-6560\/aa5aa4","article-title":"Absorbed dose evaluation of Auger electron-emitting radionuclides: impact of input decay spectra on dose point kernels and S-values","volume":"62","author":"Falzone","year":"2017","journal-title":"Phys. Med. Biol."},{"issue":"12","key":"2026100509320201400_cit80","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1118\/1.597227","article-title":"Dosimetry of Auger-electron-emitting radionuclides: Report No. 3 of AAPM Nuclear Medicine Task Group No. 6","volume":"21","author":"Humm","year":"1994","journal-title":"Med. Phys."},{"issue":"7","key":"2026100509320201400_cit81","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3109\/02841869609104045","article-title":"Calculation of equivalent dose for Auger electron emitting radionuclides distributed in human organs","volume":"35","author":"Goddu","year":"1996","journal-title":"Acta Oncol."},{"issue":"3","key":"2026100509320201400_cit82","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.icrp.2008.10.004","article-title":"ICRP Publication 107. Nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann. ICRP"},{"issue":"2","key":"2026100509320201400_cit83","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/ijms25020933","article-title":"Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides","volume":"25","author":"Kaneda-Nakashima","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"2026100509320201400_cit84","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/09553000802395527","article-title":"Auger processes in the 21st century","volume":"84","author":"Howell","year":"2008","journal-title":"Int. J. Radiat. Biol."},{"key":"2026100509320201400_cit85","doi-asserted-by":"publisher","first-page":"216764","DOI":"10.1016\/j.ccr.2025.216764","article-title":"Coordination chemistry of emerging Meitner-Auger electron-emitting radiometals for targeted radionuclide therapy","volume":"542","author":"Stec","year":"2025","journal-title":"Coord. Chem. Rev."},{"issue":"45","key":"2026100509320201400_cit86","doi-asserted-by":"publisher","first-page":"12356","DOI":"10.1021\/jp904977z","article-title":"Resonant X-ray enhancement of the Auger effect in high-Z atoms, molecules, and nanoparticles: potential biomedical applications","volume":"113","author":"Pradhan","year":"2009","journal-title":"J. Phys. Chem. A"},{"issue":"7","key":"2026100509320201400_cit87","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/0008-5472.Can-17-1958","article-title":"Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models","volume":"78","author":"Sharma","year":"2018","journal-title":"Cancer Res."},{"issue":"7","key":"2026100509320201400_cit88","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1524\/ract.2012.1935","article-title":"Polymersomes as nano-carriers to retain harmful recoil nuclides in alpha radionuclide therapy: a feasibility study","volume":"100","author":"Thijssen","year":"2012","journal-title":"Radiochim. Acta"},{"issue":"1","key":"2026100509320201400_cit89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s10238-023-01262-3","article-title":"Recent nanotheranostic approaches in cancer research","volume":"24","author":"Gupta","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"2026100509320201400_cit90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1140\/epja\/s10050-019-00010-0","article-title":"Measurement of 139La(p,x) cross sections from 35\u221260 MeV by stacked-target activation","volume":"56","author":"Morrell","year":"2020","journal-title":"Eur. Phys. J. A"},{"issue":"1","key":"2026100509320201400_cit91","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40658-016-0144-5","article-title":"Physics of pure and non-pure positron emitters for PET: a review and a discussion","volume":"3","author":"Conti","year":"2016","journal-title":"EJNMMI physics"},{"issue":"12","key":"2026100509320201400_cit92","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.1039\/c5sc02607e","article-title":"Control of cerium oxidation state through metal complex secondary structures","volume":"6","author":"Levin","year":"2015","journal-title":"Chem. Sci."},{"issue":"15","key":"2026100509320201400_cit93","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.1021\/ic4010246","article-title":"Solution thermodynamic stability of complexes formed with the octadentate hydroxypyridinonate ligand 3,4,3-LI(1,2-HOPO): a critical feature for efficient chelation of lanthanide(IV) and actinide(IV) ions","volume":"52","author":"Deblonde","year":"2013","journal-title":"Inorg. Chem."},{"issue":"14","key":"2026100509320201400_cit94","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.1021\/ic300757k","article-title":"Aqueous complexation of thorium(IV), uranium(IV), neptunium(IV), plutonium(III\/IV), and cerium(III\/IV) with DTPA","volume":"51","author":"Brown","year":"2012","journal-title":"Inorg. Chem."},{"key":"2026100509320201400_cit95","first-page":"176","article-title":"Chapter 15 - Interpreting Laboratory Tests","volume-title":"Textbook of Family Medicine","author":"Warner","year":"2011","edition":"8"},{"issue":"7","key":"2026100509320201400_cit96","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1021\/cb1000636","article-title":"Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents","volume":"5","author":"Nayak","year":"2010","journal-title":"ACS Chem. Biol."},{"issue":"4","key":"2026100509320201400_cit97","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0008-6215(98)00158-X","article-title":"DNA hydrolysis by cerium(IV)\u2212saccharide complexes","volume":"309","author":"Kajimura","year":"1998","journal-title":"Carbohydr. Res."},{"key":"2026100509320201400_cit98","first-page":"242334","article-title":"Development of 134Ce-PSMA-617 for Auger electron therapy and PET imaging of prostate cancer","volume":"65","author":"Bobba","year":"2024","journal-title":"J. Nucl. Med."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00722","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4789\/68125906\/mp6c00722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4789\/68125906\/mp6c00722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:49:27Z","timestamp":1791208167000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/4789\/5397913\/134Ce-134La-Radiotheranostics-from-PET-Surrogation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":98,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00722","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}